CTCAE (Common Terminology Criteria for Adverse Events) is the standardized oncology grading system used across chemotherapy, immunotherapy, radiation, and clinical trials to classify treatment-related toxicity severity from Grade 1 (mild) to Grade 5 (death). [Official reference link](https://dctd.cancer.gov/research/ctep-trials/for-sites/adverse-events/ctcae-v5-5x7.pdf) --- | Grade | Meaning | Typical Action | |---|---|---| | 1 | Mild | Continue therapy | | 2 | Moderate | Hold therapy ± steroids | | 3 | Severe | High-dose steroids; admit | | 4 | Life-threatening | Usually permanent discontinuation | | 5 | Death | — | --- ### HPB-Relevant immune related adverse events (irAE) - Hepatitis - Colitis - Pancreatitis - Cholangitis-like injury - Endocrinopathies --- > [!tip] > Immune toxicities are inflammatory syndromes, not classic cytotoxic chemotherapy side effects. > [!warning] > Avoid infliximab in severe immune-mediated hepatitis.